Spero Therapeutics, Inc. (SPRO) stock

SPRONasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30

$1.00−0.00 (-0.01%)

Close on Nov 13, 2026Market cap $58.23MP/E –Yield –

Spero Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Spero Therapeutics's price to sales ratio was 1.3× on Nov 11, 2026, against 3.3× a year earlier. Over the last 5 years it ranged from 0.4× to 29.6×, with a median of 1.7×.

Price to Sales Ratio at the end of each year

Period	Period end	Value	Change (pts)
2026	Nov 11, 2026	1.3×	−2.0
2025	Dec 31, 2025	3.2×	+2.7
2024	Dec 31, 2024	0.5×	−0.5
2023	Dec 29, 2023	1.0×	−7.4
2022	Dec 30, 2022	8.4×	−21.2
2021	Dec 31, 2021	29.6×	−32.4
2020	Dec 31, 2020	62.0×	+51.0
2019	Dec 31, 2019	11.1×	−23.2
2018	Dec 31, 2018	34.2×	–

Where these numbers come from

Parsed from the XBRL in Spero Therapeutics's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing